The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary ...
When Colin Huminsky shoots on his opponents, he scores. When Huminsky’s opponents shoot on him, he still scores. The Huntley ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Oral nerandomilast doses of 9 mg and 18 mg were ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Two differing nerandomilast doses were assessed against ...
Toby Maher, MD, PhD, professor of clinical medicine, Keck Medicine of USC, discusses the impact of changes in lung function in patients with idiopathic pulmonary fibrosis (IPF). How does the rate of ...
Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory properties. Nerandomilast has been shown to slow the ...
Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.
SAN FRANCISCO — The investigational oral agent nerandomilast was superior to placebo at slowing the decline in forced vital capacity (FVC) among patients with progressive pulmonary fibrosis (PF), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback